drugset
drugset / Trial / NCT02559024

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02559024 ↗

Phase 1 Terminated 4 enrolled Providence Health & Services MedImmune LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.

Timeline

Start
2016-03-14
Primary completion
2018-10
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI6469 Monoclonal antibody 0.4 mg/kg Intravenous

Indications

colorectal cancer